N-(F-18)-Flouoroacetyl-D-Glucosamine: A New Positron Labeled Pharmaceutical for Cancer Study

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

In order to evaluate the role of hexosamine metabolism in tumor tissue, we studied the biodistribution of N-(F-18)- fluoroacetyl-D-glucosamine (FAGlu) in male Donryu rats bearing poorly differentiated hepatomas (AH109A and AH272). Compare with the former result of the high tumor uptake of FAGlu in C3H/He mice bearing well differentiated spontaneous hepatoma, the tumor uptakes of FAGlu in these tumors showed the lower values. This suggested that spontaneous hepatoma maintained a high activity of glucosamine metabolism, while poorly differentiated hepatoma had little activity. Metabolism of glucosamine in tumor tissue may be another marker for characterizing tumors. We also discuss the tissue distribution of new F-18 labeled hexosamines, N-(F-18)-fluoroacetyl-D-mannosamine and N-(F-18)- fluoroacetyl-D-galactosamine in tumor bearing rats. © 1992, Tohoku University Medical Press. All rights reserved.

Cite

CITATION STYLE

APA

Fujiwara, T., Itoh, M., Kubota, K., Sato, T., Takahashi, J., Abe, Y., … Sato, K. (1992). N-(F-18)-Flouoroacetyl-D-Glucosamine: A New Positron Labeled Pharmaceutical for Cancer Study. Tohoku Journal of Experimental Medicine, 168(2), 317–321. https://doi.org/10.1620/tjem.168.317

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free